- Pfizer Inc (NYSE:PFE) would supply up to 6 million courses of its COVID-19 antiviral treatment to NGO Global Fund for low- and middle-income countries.
- The company said Paxlovid treatment courses would be available for procurement through Global Fund’s COVID-19 Response Mechanism to 132 low- and middle-income countries this year, subject to local regulatory clearances.
- Eligible countries will be offered treatment courses according to Pfizer’s tiered pricing approach, where all low- and lower-middle-income countries will pay a not-for-profit price.
- Also Read: Pfizer’s COVID-19 Pill Benefited Only Older Adults, New Israel-Based Study Shows.
- Additional contractual details of the agreement were not disclosed.
- Pfizer has made a deal with several generic drugmakers to produce its treatment at a lower price for developing countries.
- “This agreement with Global Fund is a critical step that will boost equitable access for high-risk patients in low-and-middle-income countries,” Chief Executive Officer Albert Bourla said in a statement.
- Price Action: PFE shares are up 1.24% at $44.47 on the last check Thursday.
- Photo via Wikimedia Commons
Elon Musk Turns Battery Expert, Housing Prices Expected To Cool Off In Overvalued Markets, Dollar Goes Parabolic: 5 Key Stories You May Have Missed From The Weekend
After the financial markets plummeted Friday in reaction to hawkish Fed commentary, discussions centered around whether the major averages have taken a fresh leg down.
Cryptocurrencies, which trade 24/7, were seen extending their weakness into the weekend. Against this backdrop, here's a recap of a few major headlines that hit the wire over the weekend.
